Alzheimer's Society comment on Etanercept and TNF Alpha protein

These numbers are rising and investment in dementia research is an essential part of confronting this devastating condition.

On the surface these results are exciting but we need to treat the study with caution. There are large gaps in the research, which only involved a small pilot group and we cannot draw any conclusions until a controlled trial is carried out.

We have concerns about the potential cost and practicalities of a treatment that has to be injected into patient's spines - a procedure that will require trained staff and special facilities.

It is very encouraging to see alternative ways to treat Alzheimer's disease being explored. We need to see much wider investment in dementia research in the UK.

Dr Susanne Sorensen
Head of research
Alzheimer's Society